IP Library Granted Patent US 10,450,302
Granted Patent B2
US 10,450,302 · App. 15/573,272 · Granted Oct 22, 2019

Methods of treating inflammation or neuropathic pain

Inventors: Jacqueline Lorayne Blankman (San Diego, CA); Jason Robert Clapper (San Diego, CA); R. Alan B. Ezekowitz (Princeton, NJ); Iain Peter Fraser (Scotch Plains, NJ); Cheryl A. Grice (Encinitas, CA); Todd K. Jones (Solana Beach, CA); Gary Paul O'Neill (San Diego, CA); Archie Wayne Thurston, Jr. (O'Fallon, MO); Channing Rodney Beals (San Diego, CA)
Assignee: LUNDBECK LA JOLLA RESEARCH CENTER, INC.
C07D403/10A61K31/495A61P29/00C07D295/205
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,450,302
App. No.
15/573,272
Granted
Oct 22, 2019
Kind
B2
Abstract

Provided herein are methods of treating inflammation or neuropathic pain using an effective dose of a monoacylglycerol lipase inhibitor or a composition thereof.

Claims (10)

1. A method of treating Tourette Syndrome in a patient in need thereof, comprising administering to the patient in need thereof an effective dose of 1,1,1,3,3,3-hexafluoropropan-2-yl 4-(2-(pyrrolidin-1-yl)-4-(trifluoromethyl)benzyl)piperazine-1-carboxylate (Compound 1), or a pharmaceutically acceptable salt thereof.

2. The method of claim 1 , wherein the effective dose is from about 1 mg to about 100 mg.

3. The method of claim 1 , wherein the steady state plasma AUC 0-24 of Compound 1 is at least 0.05 μM·hr after administration of the effective dose.

4. The method of claim 1 , wherein the effective dose is from about 1 mg to about 50 mg.

5. The method of claim 1 , wherein the effective dose is from about 2 mg to about 25 mg.

6. The method of claim 1 , wherein the effective dose is from about 1 mg to about 15 mg.

7. The method of claim 1 , wherein the effective dose is from about 10 mg to about 25 mg.

8. The method of claim 1 , wherein Compound 1 is administered orally.

9. The method of claim 1 , wherein the effective dose is administered to the patient once per day.

10. The method of claim 1 , wherein the effective dose is administered to the patient twice per day.

Assignments (4)
CORRECTIVE ASSIGNMENT TO CORRECT THE THE RECEIVING PARTY NAME PREVIOUSLY RECORDED AT REEL: 055679 FRAME: 0885. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Jun 11, 2021
From: LUNDBECK LA JOLLA RESEARCH CENTER, INC.
To: H. LUNDBECK A/S
Reel/Frame 056544/0697 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 23, 2021
From: LUNDBECK LA JOLLA RESEARCH CENTER, INC.
To: H. LUNDBECK A/S.
Reel/Frame 055679/0885 →
CHANGE OF NAME Recorded Aug 29, 2019
From: ABIDE THERAPEUTICS, INC.
To: LUNDBECK LA JOLLA RESEARCH CENTER, INC.
Reel/Frame 050216/0415 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 20, 2017
From: BLANKMAN, JACQUELINE LORAYNE; CLAPPER, JASON ROBERT; EZEKOWITZ, R. ALAN B.; FRASER, IAIN PETER; GRICE, CHERYL A.; JONES, TODD K.; O'NEILL, GARY PAUL; THURSTON, ARCHIE WAYNE, JR.; BEALS, CHANNING RODNEY
To: ABIDE THERAPEUTICS, INC.
Reel/Frame 044454/0425 →
Continuity (3)
Provisional Application 62297670 · Feb 19, 2016
Provisional Application 62159770 · May 11, 2015
Related Publication 20180099951A1 · Apr 12, 2018
Cited By (1)
US 12,286,421